NEW YORK--(BUSINESS WIRE)--Aug. 17, 2006-- Supports Future Growth of Hyperimmune Business and Strategy to Geographically Expand Immunoglobulin Products. OMRIX Biopharmaceuticals Inc. (“OMRIX” or “The Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, recently announced that pursuant to a supply and distribution agreement dated August 10, 2006, FFF Enterprises, Inc. (“FFF”) will commence a United States Phase III open label, single arm, multi-center clinical trial for treatment of primary immune deficiency with Omr-IgG-am(TM), the Company’s intravenous immunoglobulin (“IVIG”) currently marketed outside of the U.S.
